A prospective cohort study of the value of maternal pla and anti-angiogenic factors in early pregnancy and mid patients destined to develop preeclampsia

Journal of Maternal-Fetal and Neonatal Medicine

22, 1021-1038

DOI: 10.3109/14767050902994754

Citation Report

#	Article	IF	Citations
1	Angiogenic proteins and adipocytokines as markers for prediction of preeclampsia. Expert Review of Obstetrics and Gynecology, 2010, 5, 717-725.	0.4	5
2	Should Bilateral Uterine Artery Notching Be Used in the Risk Assessment for Preeclampsia, Small-for-Gestational-Age, and Gestational Hypertension?. Journal of Ultrasound in Medicine, 2010, 29, 1103-1115.	0.8	51
3	Maternal serum screening for preeclampsia: Is performance enough?. Clinical Biochemistry, 2010, 43, 707-708.	0.8	4
4	Firstâ€trimester assessment of placenta function and the prediction of preeclampsia and intrauterine growth restriction. Prenatal Diagnosis, 2010, 30, 293-308.	1.1	114
5	Robust Early Pregnancy Prediction of Later Preeclampsia Using Metabolomic Biomarkers. Hypertension, 2010, 56, 741-749.	1.3	242
6	Microbial invasion of the amniotic cavity in preeclampsia as assessed by cultivation and sequence-based methods. Journal of Perinatal Medicine, 2010, 38, 503-13.	0.6	74
7	Leukocytes of pregnant women with small-for-gestational age neonates have a different phenotypic and metabolic activity from those of women with preeclampsia. Journal of Maternal-Fetal and Neonatal Medicine, 2010, 23, 476-487.	0.7	40
8	Abnormal Placentation, Angiogenic Factors, and the Pathogenesis of Preeclampsia. Obstetrics and Gynecology Clinics of North America, 2010, 37, 239-253.	0.7	152
9	First- and Second-Trimester Screening for Preeclampsia and Intrauterine Growth Restriction. Clinics in Laboratory Medicine, 2010, 30, 727-746.	0.7	15
10	The preeclampsia biomarkers soluble fms-like tyrosine kinase-1 and placental growth factor: current knowledge, clinical implications and future application. European Journal of Obstetrics, Gynecology and Reproductive Biology, 2010, 151, 122-129.	0.5	58
11	New markers in preeclampsia. Clinica Chimica Acta, 2010, 411, 1591-1595.	0.5	44
12	Pre-eclampsia. Lancet, The, 2010, 376, 631-644.	6.3	2,648
13	Angiogenic proteins as aid in the diagnosis and prediction of preeclampsia. Scandinavian Journal of Clinical and Laboratory Investigation, 2010, 70, 73-78.	0.6	6
14	Serum and plasma determination of angiogenic and anti-angiogenic factors yield different results: The need for standardization in clinical practice. Journal of Maternal-Fetal and Neonatal Medicine, 2010, 23, 820-827.	0.7	22
15	An imbalance between angiogenic and anti-angiogenic factors precedes fetal death in a subset of patients: results of a longitudinal study. Journal of Maternal-Fetal and Neonatal Medicine, 2010, 23, 1384-1399.	0.7	57
16	Maternal plasma concentrations of angiogenic/anti-angiogenic factors are of prognostic value in patients presenting to the obstetrical triage area with the suspicion of preeclampsia. Journal of Maternal-Fetal and Neonatal Medicine, 2011, 24, 1187-1207.	0.7	118
17	Preeclampsia, a Disease of the Maternal Endothelium. Circulation, 2011, 123, 2856-2869.	1.6	838
18	The Role of Serum Markers and Uterine Artery Doppler in Identifying At-Risk Pregnancies. Clinics in Perinatology, 2011, 38, 1-19.	0.8	26

#	Article	IF	Citations
19	Angiogenic Factors and Preeclampsia. Seminars in Nephrology, 2011, 31, 33-46.	0.6	374
20	Preeclampsia and the anti-angiogenic state. Pregnancy Hypertension, 2011, 1, 17-21.	0.6	89
21	Circulating predictive biomarkers in preeclampsia. Pregnancy Hypertension, 2011, 1, 28-42.	0.6	27
22	Hypertension and Kidney Disease in Pregnancy: Introduction. Seminars in Nephrology, 2011, 31, 1-3.	0.6	0
23	Decreased PAPP-A is associated with preeclampsia, premature delivery and small for gestational age infants but not with placental abruption. European Journal of Obstetrics, Gynecology and Reproductive Biology, 2011, 157, 48-52.	0.5	65
24	Angiogenic Factors and Renal Disease in Pregnancy. Case Reports in Obstetrics and Gynecology, 2011, 2011, 1-4.	0.2	4
25	Epistasis between COMT and MTHFR in Maternal-Fetal Dyads Increases Risk for Preeclampsia. PLoS ONE, 2011, 6, e16681.	1.1	49
26	Contemporary prediction of preeclampsia. Current Opinion in Obstetrics and Gynecology, 2011, 23, 65-71.	0.9	43
28	The â€œGreat Obstetrical Syndromesâ€•are associated with disorders of deep placentation. American Journal of Obstetrics and Gynecology, 2011, 204, 193-201.	0.7	1,177
29	Circulating angiogenic and antiangiogenic factors in women with eclampsia. American Journal of Obstetrics and Gynecology, 2011, 204, 152.e1-152.e9.	0.7	88
30	Midpregnancy levels of angiogenic markers in relation to maternal characteristics. American Journal of Obstetrics and Gynecology, 2011, 204, 244.e1-244.e12.	0.7	34
31	Early prediction and prevention of pre-eclampsia. Best Practice and Research in Clinical Obstetrics and Gynaecology, 2011, 25, 343-354.	1.4	64
32	Influence of the vascular endothelial growth factor on the development of severe pre-eclampsia or HELLP syndrome. Archives of Gynecology and Obstetrics, 2011, 284, 551-557.	0.8	21
33	Pharmacokinetic Study of ZS-1, a Targeted Peptide to NCI-H1299, in Rats Following Intravenous Administration. Chromatographia, 2011, 73, 177-181.	0.7	0
34	Threshold of Soluble Fms-Like Tyrosine Kinase 1/Placental Growth Factor Ratio for the Imminent Onset of Preeclampsia. Hypertension, 2011, 58, 859-866.	1.3	40
35	Placental lesions associated with maternal underperfusion are more frequent in early-onset than in late-onset preeclampsia. Journal of Perinatal Medicine, 2011, 39, 641-52.	0.6	228
36	Vaginal Progesterone to Reduce the Rate of Preterm Birth and Neonatal Morbidity: A Solution at Last. Women's Health, 2011, 7, 501-504.	0.7	18
37	Biomarkers in Preeclampsia. , 2011, , 385-426.		3

#	Article	IF	Citations
38	Angiogenic growth factors in the diagnosis and prediction of pre-eclampsia. Clinical Science, 2012, 122, 43-52.	1.8	121
39	Angiogenic Factors in Superimposed Preeclampsia. Hypertension, 2012, 59, 740-746.	1.3	138
40	The vascular endothelial growth factor family in adverse pregnancy outcomes. Human Reproduction Update, 2012, 18, 436-457.	5.2	162
41	Angiogenic imbalance and plasma lipid alterations in women with preeclampsia from a developing country. Growth Factors, 2012, 30, 158-166.	0.5	14
42	Angiogenic Factors and the Risk of Adverse Outcomes in Women With Suspected Preeclampsia. Circulation, 2012, 125, 911-919.	1.6	526
43	Timing of ischemic insult alters fetal growth trajectory, maternal angiogenic balance, and markers of renal oxidative stress in the pregnant rat. American Journal of Physiology - Regulatory Integrative and Comparative Physiology, 2012, 303, R658-R664.	0.9	16
44	The Promise of Angiogenic Markers for the Early Diagnosis and Prediction of Preeclampsia. Clinical Chemistry, 2012, 58, 837-845.	1.5	108
45	Circulating Angiogenic Factors and Risk of Adverse Maternal and Perinatal Outcomes in Twin Pregnancies With Suspected Preeclampsia. Hypertension, 2012, 60, 451-458.	1.3	84
46	Low Placental Growth Factor Across Pregnancy Identifies a Subset of Women With Preterm Preeclampsia. Hypertension, 2012, 60, 239-246.	1.3	80
47	Glycogen Phosphorylase Isoenzyme BB Plasma Concentration Is Elevated in Pregnancy and Preterm Preeclampsia. Hypertension, 2012, 59, 274-282.	1.3	11
48	Early Detection of Maternal Risk for Preeclampsia. ISRN Obstetrics & Gynecology, 2012, 2012, 1-7.	1.2	20
49	Late-onset preeclampsia is associated with an imbalance of angiogenic and anti-angiogenic factors in patients with and without placental lesions consistent with maternal underperfusion. Journal of Maternal-Fetal and Neonatal Medicine, 2012, 25, 498-507.	0.7	136
50	Angiogenic biomarkers for prediction of maternal and neonatal complications in suspected preeclampsia. Journal of Maternal-Fetal and Neonatal Medicine, 2012, 25, 2651-2657.	0.7	63
51	Examining the correlation between placental and serum placenta growth factor in preeclampsia. American Journal of Obstetrics and Gynecology, 2012, 207, 140.e1-140.e6.	0.7	21
52	Recent biomarkers for the identification of patients at risk for preeclampsia: the role of uteroplacental ischemia. Expert Opinion on Medical Diagnostics, 2012, 6, 121-130.	1.6	19
53	Angiogenic and Fibrinolytic Factors in Blood During the First Half of Pregnancy and Adverse Pregnancy Outcomes. Obstetrics and Gynecology, 2012, 119, 1190-1200.	1.2	56
54	Accuracy of circulating placental growth factor, vascular endothelial growth factor, soluble fmsâ€like tyrosine kinase 1 and soluble endoglin in the prediction of preâ€eclampsia: a systematic review and metaâ€analysis. BJOG: an International Journal of Obstetrics and Gynaecology, 2012, 119, 778-787.	1.1	210
55	Second trimester anti-angiogenic proteins and preeclampsia. Pregnancy Hypertension, 2012, 2, 158-163.	0.6	15

#	Article	IF	Citations
56	The need to redefine preeclampsia. Expert Opinion on Medical Diagnostics, 2012, 6, 347-357.	1.6	6
57	Relationships among maternal nutrient intake and placental biomarkers during the 1st trimester in low-income women. Archives of Gynecology and Obstetrics, 2012, 285, 891-899.	0.8	10
58	The sFlt-1/PlGF ratio in different types of hypertensive pregnancy disorders and its prognostic potential in preeclamptic patients. American Journal of Obstetrics and Gynecology, 2012, 206, 58.e1-58.e8.	0.7	339
59	First trimester maternal serum PlGF, free Î²-hCG, PAPP-A, PP-13, uterine artery Doppler and maternal history for the prediction of preeclampsia. Placenta, 2012, 33, 495-501.	0.7	107
60	Fetal Growth Restriction (FGR)â€"Fetal Evaluation and Antepartum Intervention. Current Obstetrics and Gynecology Reports, 2013, 2, 112-121.	0.3	1
61	Is serum placental growth factor more effective as a biomarker in predicting early onset preeclampsia in early second trimester than in first trimester of pregnancy?. Archives of Gynecology and Obstetrics, 2013, 287, 865-873.	0.8	20
62	The Role of Angiogenic and Antiangiogenic Factors in the Second Trimester in the Prediction of Preeclampsia in Pregnant Women With Type 1 Diabetes. Diabetes Care, 2013, 36, 3671-3677.	4.3	28
63	Evaluation of a rapid and simple placental growth factor test in hypertensive disorders of pregnancy. Hypertension Research, 2013, 36, 457-462.	1.5	13
64	Serum placental growth factor as a predictor of early onset preeclampsia in overweight/obese pregnant women. Journal of the American Society of Hypertension, 2013, 7, 137-148.	2.3	21
65	Maternal plasma concentrations of angiogenic/antiangiogenic factors in the third trimester of pregnancy to identify the patient at risk for stillbirth at or near term and severe late preeclampsia. American Journal of Obstetrics and Gynecology, 2013, 208, 287.e1-287.e15.	0.7	122
66	miR-210 Inhibits Trophoblast Invasion and Is a Serum Biomarker for Preeclampsia. American Journal of Pathology, 2013, 183, 1437-1445.	1.9	126
67	Placental growth factor and soluble fms-like tyrosine kinase-1 are useful markers for the prediction of preeclampsia but not for small for gestational age neonates: a longitudinal study. European Journal of Obstetrics, Gynecology and Reproductive Biology, 2013, 171, 225-230.	0.5	31
68	Comparison of placental growth factor and fetal flow Doppler ultrasonography to identify fetal adverse outcomes in women with hypertensive disorders of pregnancy: an observational study. BMC Pregnancy and Childbirth, 2013, 13, 161.	0.9	22
69	Circulating Levels of Neutrophil Gelatinaseâ€"Associated Lipocalin (NGAL) Correlate With the Presence and Severity of Preeclampsia. Reproductive Sciences, 2013, 20, 1083-1089.	1.1	28
70	Preeclampsia is associated with an elevation of plasma sMet concentrations in the second trimester. Journal of Maternal-Fetal and Neonatal Medicine, 2013, 26, 860-865.	0.7	2
71	Maternal plasma concentrations of sST2 and angiogenic/anti-angiogenic factors in preeclampsia. Journal of Maternal-Fetal and Neonatal Medicine, 2013, 26, 1359-1370.	0.7	43
72	Perfusion with magnesium sulfate increases sFlt-1 secretion only in the fetal side of placenta of women with preeclampsia. Journal of Maternal-Fetal and Neonatal Medicine, 2013, 26, 116-122.	0.7	5
73	Evidence of an imbalance of angiogenic/antiangiogenic factors in massive perivillous fibrin deposition (maternal floor infarction): a placental lesion associated with recurrent miscarriage and fetal death. American Journal of Obstetrics and Gynecology, 2013, 208, 310.e1-310.e11.	0.7	60

#	Article	IF	Citations
74	Endostatin levels and the risk of subsequent preeclampsia. European Journal of Obstetrics, Gynecology and Reproductive Biology, 2013, 170, 396-400.	0.5	4
75	Endoglin in Amniotic Fluid as a Risk Factor for the Subsequent Development of Bronchopulmonary Dysplasia. American Journal of Reproductive Immunology, 2013, 69, 105-123.	1.2	22
76	Renal Physiology and Disease in Pregnancy. , 2013, , 2689-2761.		19
77	The role and challenges of biomarkers in spontaneous preterm birth and preeclampsia. Fertility and Sterility, 2013, 99, 1117-1123.	0.5	36
78	Emerging New Biomarkers of Preeclampsia. Advances in Chronic Kidney Disease, 2013, 20, 271-279.	0.6	47
79	Can changes in angiogenic biomarkers between the first and second trimesters of pregnancy predict development of preâ€eclampsia in a lowâ€risk nulliparous patient population?. BJOG: an International Journal of Obstetrics and Gynaecology, 2013, 120, 1183-1191.	1.1	89
80	Evidence for extraplacental sources of circulating angiogenic growth effectors in human pregnancy. Placenta, 2013, 34, 1170-1176.	0.7	20
81	Microvascular Remodelling in Preeclampsia: Quantifying Capillary Rarefaction Accurately and Independently Predicts Preeclampsia. American Journal of Hypertension, 2013, 26, 1162-1169.	1.0	15
82	An Elevated Maternal Plasma Soluble fms-Like Tyrosine Kinase-1 to Placental Growth Factor Ratio at Midtrimester Is a Useful Predictor for Preeclampsia. Obstetrics and Gynecology International, 2013, 2013, 1-8.	0.5	36
83	Placental growth factor (PlGF): a key to optimizing fetal growth. Journal of Maternal-Fetal and Neonatal Medicine, 2013, 26, 995-1002.	0.7	80
84	Angiogenic factors in preeclampsia. Current Opinion in Nephrology and Hypertension, 2013, 22, 643-650.	1.0	27
85	PRE-ECLAMPSIA: ONE NAME, TWO CONDITIONS â€“ THE CASE FOR EARLY AND LATE DISEASE BEING DIFFERENT. Fetal and Maternal Medicine Review, 2013, 24, 32-37.	0.3	1
86	The course of angiogenic factors in early- vs. late-onset preeclampsia and HELLP syndrome. Journal of Perinatal Medicine, 2013, 41, 511-516.	0.6	64
87	Clinical characterization and outcomes of preeclampsia with normal angiogenic profile. Hypertension in Pregnancy, 2013, 32, 189-201.	0.5	130
88	Cost and resource implications with serum angiogenic factor estimation in the triage of preâ€eclampsia. BJOG: an International Journal of Obstetrics and Gynaecology, 2013, 120, 1224-1232.	1.1	41
89	Low-Molecular Weight Heparin Increases Circulating sFlt-1 Levels and Enhances Urinary Elimination. PLoS ONE, 2014, 9, e85258.	1.1	31
90	First Trimester Screening of Circulating C19MC microRNAs Can Predict Subsequent Onset of Gestational Hypertension. PLoS ONE, 2014, 9, e113735.	1.1	36
91	Clinical applications of biomarkers in preeclampsia. Biomarkers in Medicine, 2014, 8, 459-470.	0.6	8

#	Article	IF	Citations
92	Discordant clinical presentations of preeclampsia and intrauterine fetal growth restriction with similar pro- and anti-angiogenic profiles. Journal of Maternal-Fetal and Neonatal Medicine, 2014, 27, 1854-1859.	0.7	40
93	Placental lesions of vascular insufficiency are associated with anti-angiogenic state in women with preeclampsia. Hypertension in Pregnancy, 2014, 33, 427-439.	0.5	38
94	First trimester screening cannot predict adverse outcomes yet. Prenatal Diagnosis, 2014, 34, 668-676.	1.1	21
95	Plasma concentrations of angiogenic/anti-angiogenic factors have prognostic value in women presenting with suspected preeclampsia to the obstetrical triage area: a prospective study. Journal of Maternal-Fetal and Neonatal Medicine, 2014, 27, 132-144.	0.7	68
96	Angiogenic biomarkers for prediction of early preeclampsia onset in high-risk women. Journal of Maternal-Fetal and Neonatal Medicine, 2014, 27, 1038-1048.	0.7	36
97	Placental Pathology in Early-Onset and Late-Onset Fetal Growth Restriction. Fetal Diagnosis and Therapy, 2014, 36, 117-128.	0.6	234
98	Hypoproteinemia in the second trimester among patients with preeclampsia prior to the onset of clinical symptoms. Hypertension in Pregnancy, 2014, 33, 55-60.	0.5	6
99	The association of circulating angiogenic factors and HbA1c with the risk of preeclampsia in women with preexisting diabetes. Hypertension in Pregnancy, 2014, 33, 81-92.	0.5	45
100	Prediction of preeclampsia and induced delivery at <34Âweeks gestation by sFLT-1 and PlGF in patients with abnormal midtrimester uterine Doppler velocimetry: a prospective cohort analysis. BMC Pregnancy and Childbirth, 2014, 14, 292.	0.9	28
101	ANGIOGENIC IMBALANCES IN THE PATHOGENESIS OF PREGNANCY COMPLICATIONS. Fetal and Maternal Medicine Review, 2014, 25, 42-58.	0.3	0
102	Statistical regression model of standard and new laboratory markers and its usefulness in prediction of preeclampsia. Journal of Maternal-Fetal and Neonatal Medicine, 2014, 27, 388-392.	0.7	6
103	New directions in the prediction of pre-eclampsia. Australian and New Zealand Journal of Obstetrics and Gynaecology, 2014, 54, 101-107.	0.4	28
104	Firstâ€trimester uterine artery Doppler and adverse pregnancy outcome: a metaâ€analysis involving 55â€‰974 women. Ultrasound in Obstetrics and Gynecology, 2014, 43, 500-507.	0.9	207
105	Angiogenic Factors in Diagnosis, Management, and Research in Preeclampsia. Hypertension, 2014, 63, 198-202.	1.3	106
106	Expression of placenta growth factor, soluble fmsâ€like tyrosine kinaseâ€1, metalâ€responsive transcription factorâ€1, heme oxygenase 1 and hypoxia inducible factorâ€1Î± <scp>mRNAs</scp> in preâ€eclampsia placenta and the effect of preâ€eclampsia sera on their expression of choriocarcinoma cells. Journal of Obstetrics and Gynaecology Research, 2014, 40, 2095-2103.	0.6	11
107	Pre-eclampsia part 2: prediction, prevention and management. Nature Reviews Nephrology, 2014, 10, 531-540.	4.1	125
108	Second- and third-trimester biochemical and ultrasound markers predictive of ischemic placental disease. Seminars in Perinatology, 2014, 38, 167-176.	1.1	16
109	Implementation of the <scp>sFlt</scp>â€1/<scp>PlGF</scp> ratio for prediction and diagnosis of preâ€eclampsia in singleton pregnancy: implications for clinical practice. Ultrasound in Obstetrics and Gynecology, 2015, 45, 241-246.	0.9	196

#	Article	IF	Citations
110	New Directions in the Prediction of Preeclampsia. Obstetric Anesthesia Digest, 2015, 35, 65-66.	0.0	0
111	Angiogenesis-Related Biomarkers (sFlt-1/PLGF) in the Prediction and Diagnosis of Placental Dysfunction: An Approach for Clinical Integration. International Journal of Molecular Sciences, 2015, 16, 19009-19026.	1.8	83
112	Early Pregnancy Biomarkers in Pre-Eclampsia: A Systematic Review and Meta-Analysis. International Journal of Molecular Sciences, 2015, 16, 23035-23056.	1.8	98
113	Acute Atherosis of the Uterine Spiral Arteries: Clinicopathologic Implications. Journal of Pathology and Translational Medicine, 2015, 49, 462-471.	0.4	33
114	Full-Length Human Placental sFlt-1-e15a Isoform Induces Distinct Maternal Phenotypes of Preeclampsia in Mice. PLoS ONE, 2015, 10, e0119547.	1.1	50
115	Circulating Angiogenic Factors and the Risk of Adverse Outcomes among Haitian Women with Preeclampsia. PLoS ONE, 2015, 10, e0126815.	1.1	48
116	Is the imbalance between pro-angiogenic and anti-angiogenic factors associated with preeclampsia?. Clinica Chimica Acta, 2015, 447, 34-38.	0.5	59
117	Promising prognostic markers of Preeclampsia: New avenues in waiting. Thrombosis Research, 2015, 136, 189-195.	0.8	26
118	Modeling risk for severe adverse outcomes using angiogenic factor measurements in women with suspected preterm preeclampsia. Prenatal Diagnosis, 2015, 35, 386-393.	1.1	28
119	Firstâ€trimester screening for preâ€eclampsia: moving from personalized risk prediction to prevention. Ultrasound in Obstetrics and Gynecology, 2015, 45, 119-129.	0.9	41
120	Angiogenic biomarkers in pregnancy: defining maternal and fetal health. Acta Obstetricia Et Gynecologica Scandinavica, 2015, 94, 820-832.	1.3	23
121	Baseline placental growth factor levels for the prediction of benefit from early aspirin prophylaxis for preeclampsia prevention. Pregnancy Hypertension, 2015, 5, 280-286.	0.6	8
123	Diagnostic accuracy of the soluble Fms-like tyrosine kinase-1/placental growth factor ratio for preeclampsia: a meta-analysis based on 20 studies. Archives of Gynecology and Obstetrics, 2015, 292, 507-518.	0.8	46
124	Whole mount immunofluorescence analysis of placentas from normotensive versus preeclamptic pregnancies. Placenta, 2015, 36, 1310-1317.	0.7	8
125	Maternal plasma fetuin-A concentration is lower in patients who subsequently developed preterm preeclampsia than in uncomplicated pregnancy: a longitudinal study. Journal of Maternal-Fetal and Neonatal Medicine, 2015, 28, 1260-1269.	0.7	5
126	Ischemic placental syndrome â€“ prediction and new disease monitoring. Journal of Maternal-Fetal and Neonatal Medicine, 2016, 29, 1-7.	0.7	8
127	Molecular Mechanisms of Preeclampsia. Cold Spring Harbor Perspectives in Medicine, 2015, 5, a023473.	2.9	127
128	Tests to Predict Preeclampsia. , 2015, , 221-251.		3

#	Article	IF	Citations
129	Placental Growth Factor, Soluble fms-Like Tyrosine Kinase 1, Soluble Endoglin, IL-6, and IL-16 as Biomarkers in Preeclampsia. Mediators of Inflammation, 2016, 2016, 1-8.	1.4	26
130	Role of Extracellular Vesicles and microRNAs on Dysfunctional Angiogenesis during Preeclamptic Pregnancies. Frontiers in Physiology, 2016, 7, 98.	1.3	85
131	Bedside diagnosis of two major clinical phenotypes of hypertensive disorders of pregnancy. Ultrasound in Obstetrics and Gynecology, 2016, 48, 224-231.	0.9	26
132	Racial-ethnic differences in midtrimester maternal serum levels of angiogenic and antiangiogenic factors. American Journal of Obstetrics and Gynecology, 2016, 215, 359.e1-359.e9.	0.7	27
133	Association of first-trimester angiogenic factors with placental histological findings in late-onset preeclampsia. Placenta, 2016, 42, 44-50.	0.7	17
134	Trophoblastic debris extruded from hydatidiform molar placentae activates endothelial cells: Possible relevance to the pathogenesis of preeclampsia. Placenta, 2016, 45, 42-49.	0.7	6
135	Maternal plasma angiogenic index-1 (placental growth factor/solubleÂvascular endothelial growth) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 underperfusion: a longitudinal case-cohort study. American Journal of Obstetrics and Gynecology, 2016, 214, 629.e1-629.e17.	0.7	91
136	Circulating Maternal Total Cell-Free DNA, Cell-Free Fetal DNA and Soluble Endoglin Levels in Preeclampsia: Predictors of Adverse Fetal Outcome? A Cohort Study. Molecular Diagnosis and Therapy, 2016, 20, 135-149.	1.6	20
137	Placental growth factor and vascular endothelial growth factor serum levels in Tunisian Arab women with suspected preeclampsia. Cytokine, 2016, 79, 1-6.	1.4	18
138	New lenses to look at preeclampsia. Gynecological Endocrinology, 2016, 32, 87-90.	0.7	4
139	First-, Second-, and Third-Trimester Screening for Preeclampsia and Intrauterine Growth Restriction. Clinics in Laboratory Medicine, 2016, 36, 331-351.	0.7	31
141	Angiogenic factor imbalance early in pregnancy predicts adverse outcomes in patients with lupus and antiphospholipid antibodies: results of the PROMISSE study. American Journal of Obstetrics and Gynecology, 2016, 214, 108.e1-108.e14.	0.7	122
142	The use of angiogenic biomarkers in maternal blood to identify which SGA fetuses will require a preterm delivery and mothers who will develop pre-eclampsia. Journal of Maternal-Fetal and Neonatal Medicine, 2016, 29, 1214-1228.	0.7	63
143	Pravastatin to prevent recurrent fetal death in massive perivillous fibrin deposition of the placenta (MPFD). Journal of Maternal-Fetal and Neonatal Medicine, 2016, 29, 855-862.	0.7	43
144	Early pregnancy angiogenic proteins levels and pregnancy related hypertensive disorders. Journal of Maternal-Fetal and Neonatal Medicine, 2017, 30, 534-539.	0.7	6
145	Is an episode of suspected preterm labor that subsequently leads to a term delivery benign?. American Journal of Obstetrics and Gynecology, 2017, 216, 89-94.	0.7	21
146	The maternal plasma proteome changes as a function of gestational age in normal pregnancy: a longitudinal study. American Journal of Obstetrics and Gynecology, 2017, 217, 67.e1-67.e21.	0.7	66
147	Metformin, the aspirin of the 21st century: itsÂrole in gestational diabetes mellitus, prevention of preeclampsia and cancer, andÂthe promotion of longevity. American Journal of Obstetrics and Gynecology, 2017, 217, 282-302.	0.7	183

#	Article	IF	Citations
148	Failure of physiologic transformation of spiral arteries, endothelial and trophoblast cell activation, and acute atherosis in the basal plate of theÂplacenta. American Journal of Obstetrics and Gynecology, 2017, 216, 287.e1-287.e16.	0.7	111
149	Biomarkers in Preeclampsia. , 2017, , 555-594.		4
150	Maternal endothelial damage as a disorder shared by early preeclampsia, late preeclampsia and intrauterine growth restriction. Journal of Perinatal Medicine, 2017, 45, 793-802.	0.6	19
151	Vascular Dysfunction in Mother and Offspring During Preeclampsia: Contributions from Latin-American Countries. Current Hypertension Reports, 2017, 19, 83.	1.5	33
152	FLT1 and transcriptome-wide polyadenylation site (PAS) analysis in preeclampsia. Scientific Reports, 2017, 7, 12139.	1.6	38
153	The prediction of fetal death with a simple maternal bloodÂtest at 24-28 weeks: a role for angiogenic index-1 (PlGF/sVEGFR-1 ratio). American Journal of Obstetrics and Gynecology, 2017, 217, 682.e1-682.e13.	0.7	31
154	The role of soluble epoxide hydrolase in preeclampsia. Medical Hypotheses, 2017, 108, 81-85.	0.8	10
155	Pathophysiology of preeclampsia: an angiogenic imbalance and long-lasting systemic vascular dysfunction. Hypertension Research, 2017, 40, 305-310.	1.5	92
156	Prediction and prevention of hypertensive disorders of pregnancy. Hypertension Research, 2017, 40, 5-14.	1.5	31
157	Pathophysiology of Preeclampsia. , 2017, , 1724-1732.e2.		0
158	Genetic predisposition to preeclampsia is conferred by fetal DNA variants near FLT1, a gene involved in the regulation of angiogenesis. American Journal of Obstetrics and Gynecology, 2018, 218, 211-218.	0.7	66
159	sFlt-1/PLGF. Comprehensive Gynecology and Obstetrics, 2018, , 175-198.	0.0	0
160	Estimation of asymmetric dimethylarginine (ADMA), placental growth factor (PLGF) and pentraxin 3 (PTX 3) in women with preeclampsia. Pregnancy Hypertension, 2018, 14, 245-251.	0.6	7
161	Maternal plasma-soluble ST2 concentrations are elevated prior to the development of early and late onset preeclampsia â€“ a longitudinal study. Journal of Maternal-Fetal and Neonatal Medicine, 2018, 31, 418-432.	0.7	26
162	First and Second Trimester Serum sFlt-1/PlGF Ratio and Subsequent Preeclampsia: A Systematic Review. Journal of Obstetrics and Gynaecology Canada, 2018, 40, 618-626.	0.3	21
163	Angiogenic and antiangiogenic factors in preeclampsia. Pathology Research and Practice, 2018, 214, 7-14.	1.0	51
164	Meta-Analysis and Systematic Review to Assess the Role of Soluble FMS-Like Tyrosine Kinase-1 and Placenta Growth Factor Ratio in Prediction of Preeclampsia. Hypertension, 2018, 71, 306-316.	1.3	134
165	Screening and prevention of preâ€term preâ€eclampsia â€“ A prime time to act. Australasian Journal of Ultrasound in Medicine, 2018, 21, 187-190.	0.3	1

#	Article	IF	Citations
166	Loss of placental growth factor ameliorates maternal hypertension and preeclampsia in mice. Journal of Clinical Investigation, 2018, 128, 5008-5017.	3.9	42
167	Peripheral arterial tonometry and angiogenic biomarkers in preeclampsia. Hypertension in Pregnancy, 2018, 37, 197-203.	0.5	7
168	Angiogenic profile in the Finnish Genetics of Pre-Eclampsia Consortium (FINNPEC) cohort. Pregnancy Hypertension, 2018, 14, 252-259.	0.6	9
169	Predictive value of the sFlt-1 and PlGF in women at risk for preeclampsia in the south of Vietnam. Pregnancy Hypertension, 2018, 14, 37-42.	0.6	7
170	Maternal total cell-free DNA in preeclampsia and fetal growth restriction: Evidence of differences in maternal response to abnormal implantation. PLoS ONE, 2018, 13, e0200360.	1.1	34
171	The discovery of protein biomarkers in pre-eclampsia: the promising role of mass spectrometry. Biomarkers, 2018, 23, 609-621.	0.9	8
172	Integrated Systems Biology Approach Identifies Novel Maternal and Placental Pathways of Preeclampsia. Frontiers in Immunology, 2018, 9, 1661.	2.2	146
173	Angiogenic capacity in pre-eclampsia and uncomplicated pregnancy estimated by assay of angiogenic proteins and an in vitro vasculogenesis/angiogenesis test. Angiogenesis, 2019, 22, 67-74.	3.7	5
174	Risk Factor and Biomarker of Preeclampsia. , 2019, , .		1
175	Predictive Performance of PlGF (Placental Growth Factor) for Screening Preeclampsia in Asymptomatic Women. Hypertension, 2019, 74, 1124-1135.	1.3	69
176	The prediction of early preeclampsia: Results from a longitudinal proteomics study. PLoS ONE, 2019, 14, e0217273.	1.1	81
177	Screening for preeclampsia in the first trimester of pregnancy in routine clinical practice in Hungary. Journal of Biotechnology, 2019, 300, 11-19.	1.9	4
178	Prediction of preeclampsia using combination of biomarkers at 18â€“23â€¯weeks of gestation: A nested case-control study. Pregnancy Hypertension, 2019, 17, 20-27.	0.6	5
180	Placental growth factor blunts uterine artery responses to angiotensin II. BJOG: an International Journal of Obstetrics and Gynaecology, 2019, 126, 1058-1064.	1.1	5
181	Pre-eclampsia: pathogenesis, novel diagnostics and therapies. Nature Reviews Nephrology, 2019, 15, 275-289.	4.1	609
182	Longitudinal circulating placental growth factor (PlGF) and soluble FMS-like tyrosine kinase-1 (sFlt-1) concentrations during pregnancy in Asian women: a prospective cohort study. BMJ Open, 2019, 9, e028321.	0.8	9
183	ACOG. Obstetrics and Gynecology, 2019, 133, 1-1.	1.2	575
184	The profiles of soluble adhesion molecules in the â€œgreat obstetrical syndromesâ€•. Journal of Maternal-Fetal and Neonatal Medicine, 2019, 32, 2113-2136.	0.7	32

#	Article	IF	Citations
185	ELABELA plasma concentrations are increased in women with late-onset preeclampsia. Journal of Maternal-Fetal and Neonatal Medicine, 2020, 33, 5-15.	0.7	37
186	Reconciling the distinct roles of angiogenic/anti-angiogenic factors in the placenta and maternal circulation of normal and pathological pregnancies. Angiogenesis, 2020, 23, 105-117.	3.7	81
187	The role of biomarkers in predicting pre-eclampsia in high-risk women. Annals of Clinical Biochemistry, 2020, 57, 128-137.	0.8	4
188	The diagnostic value of angiogenic and antiangiogenic factors in differential diagnosis of preeclampsia. American Journal of Obstetrics and Gynecology, 2022, 226, S1048-S1058.	0.7	34
189	Imbalances in circulating angiogenic factors in the pathophysiology of preeclampsia and related disorders. American Journal of Obstetrics and Gynecology, 2022, 226, S1019-S1034.	0.7	120
190	Temperature and preeclampsia: Epidemiological evidence that perturbation in maternal heat homeostasis affects pregnancy outcome. PLoS ONE, 2020, 15, e0232877.	1.1	27
191	Diagnostic accuracy of sFlt1/PlGF ratio as a marker for preeclampsia. BMC Pregnancy and Childbirth, 2020, 20, 80.	0.9	38
192	Preeclampsia: Pathophysiology and management. Journal of Gynecology Obstetrics and Human Reproduction, 2021, 50, 101975.	0.6	56
193	Advances in biomarker development and potential application for preeclampsia based on pathogenesis. European Journal of Obstetrics and Gynecology and Reproductive Biology: X, 2021, 9, 100119.	0.6	20
194	Prediction of preeclampsia throughout gestation with maternal characteristics and biophysical and biochemical markers: a longitudinal study. American Journal of Obstetrics and Gynecology, 2022, 226, 126.e1-126.e22.	0.7	18
195	Unravelling the potential of angiogenic factors for the early prediction of preeclampsia. Hypertension Research, 2021, 44, 756-769.	1.5	7
196	Identification and validation of key non-coding RNAs and mRNAs using co-expression network analysis in pre-eclampsia. Medicine (United States), 2021, 100, e25294.	0.4	11
197	The ROBINSâ€Ι and the NOS had similar reliability but differed in applicability: A random sampling observational studies of systematic reviews/metaâ€analysis. Journal of Evidence-Based Medicine, 2021, 14, 112-122.	0.7	33
198	The Role of Biomarkers and Imaging to Predict Preeclampsia and Subsequent Cardiovascular Dysfunction. Current Treatment Options in Cardiovascular Medicine, 2021, 23, 1.	0.4	2
199	Mean arterial pressure for predicting preeclampsia in Asian women: a longitudinal cohort study. BMJ Open, 2021, 11, e046161.	0.8	5
200	New-onset postpartum preeclampsia: epigenetic mechanism and prediction. Journal of Maternal-Fetal and Neonatal Medicine, 2022, 35, 7179-7187.	0.7	2
201	Upregulated LncZBTB39 in pre-eclampsia and its effects on trophoblast invasion and migration via antagonizing the inhibition of miR-210 on THSD7A expression. European Journal of Obstetrics, Gynecology and Reproductive Biology, 2020, 248, 164-171.	0.5	7
202	Gestational Hypertension and Preeclampsia. Obstetrics and Gynecology, 2020, 135, e237-e260.	1.2	1,063

#	Article	IF	Citations
203	Plasma Concentrations of Soluble Endoglin versus Standard Evaluation in Patients with Suspected Preeclampsia. PLoS ONE, 2012, 7, e48259.	1.1	49
204	Placental Growth Factor for the Prediction of Adverse Outcomes in Patients with Suspected Preeclampsia or Intrauterine Growth Restriction. PLoS ONE, 2012, 7, e50208.	1.1	67
205	In Vivo Experiments Reveal the Good, the Bad and the Ugly Faces of sFlt-1 in Pregnancy. PLoS ONE, 2014, 9, e110867.	1.1	40
206	First trimester screening of circulating C19MC microRNAs and the evaluation of their potential to predict the onset of preeclampsia and IUGR. PLoS ONE, 2017, 12, e0171756.	1.1	91
207	The prediction of late-onset preeclampsia: Results from a longitudinal proteomics study. PLoS ONE, 2017, 12, e0181468.	1.1	84
208	Angiogenic factors and the risk of preeclampsia: A systematic review and meta-analysis. International Journal of Reproductive BioMedicine, 2019, 17, 1.	0.5	15
209	Placental growth factor (alone or in combination with soluble fms-like tyrosine kinase 1) as an aid to the assessment of women with suspected pre-eclampsia: systematic review and economic analysis. Health Technology Assessment, 2016, 20, 1-160.	1.3	31
210	Dysregulated circulating miRNAs in preeclampsia. Biomedical Reports, 2016, 5, 686-692.	0.9	49
211	Preeclampsia: Definitions, screening tools and diagnostic criteria in the supersonic era. World Journal of Obstetrics and Gynecology, 2014, 3, 98.	0.5	1
213	Prediction of preeclampsia using angiogenic and antiangiogenic factors. Hypertension Research in Pregnancy, 2013, 1, 66-70.	0.1	0
214	Perbedaan Rerata Kadar Soluble Fms-Like Tyrosine Kinase-1 (Sflt-1) Serum pada Penderita Early Onset, Late Onset Preeklampsia Berat / Eklampsia dan Kehamilan Normal. Jurnal Kesehatan Andalas, 2016, 5, .	0.1	0
215	Placental Growth Factor Level is Lower in Early-Onset Preeclampsia, while Tumor Necrosis Factor Alpha Level does not Show any Difference between Early and Late Onset Preeclampsia. Majalah Obstetri Dan Ginekologi Indonesia, 0, , .	0.0	0
216	Angiogenesis Factors and Uterine Artery Doppler Ultrasound Resistance Index and Pulsatility Index in Pregnancies with High-Risk of Preeclampsia. Journal of Clinical Case Reports, 2017, 7, .	0.0	0
217	Evaluation of Serum Biomarkers and Other Diagnostic Modalities for Early Diagnosis of Preeclampsia. Journal of Family & Reproductive Health, 0, , .	0.4	6
218	ROLE OF GESTATIONAL ENDOTHELIALOPATHY IN DEVELOPMENT OF INTRAUTERINE GROWTH RESTRICTION IN PREGNANT WOMEN WITH PLACENTAL DYSFUNCTION. International Medical Journal, 2020, , 33-37.	0.1	0
219	Expert consensus: Indication criteria and screening strategy for preeclampsia using the serum sFlt-1/PlGF ratio at 18â€“36 weeks of gestation in women at imminent/basal risk of preeclampsia under insurance coverage. Hypertension Research in Pregnancy, 2020, 8, 51-56.	0.1	3
221	The imbalance in expression of angiogenic and anti-angiogenic factors as candidate predictive biomarker in preeclampsia. Iranian Journal of Reproductive Medicine, 2015, 13, 251-62.	0.8	15
222	Evaluation of Serum Biomarkers and Other Diagnostic Modalities for Early Diagnosis of Preeclampsia. Journal of Family & Reproductive Health, 2019, 13, 56-69.	0.4	12

#	Article	IF	Citations
223	Angiogenesis and Preeclampsia. , 2022, , 165-185.		0
224	Angiogenic Biomarkers for Risk Stratification in Women with Preeclampsia. Clinical Chemistry, 2022, 68, 771-781.	1.5	8
225	The etiology of preeclampsia. American Journal of Obstetrics and Gynecology, 2022, 226, S844-S866.	0.7	140
226	Preeclampsia and eclampsia: the conceptual evolution of a syndrome. American Journal of Obstetrics and Gynecology, 2022, 226, S786-S803.	0.7	84
227	Screening for High-Risk Pregnancy. , 2021, , 139-146.		0
242	The association between sleep-disordered breathing and maternal endothelial and metabolic markers in pregnancies complicated by obesity. Journal of Clinical Sleep Medicine, 2023, 19, 97-109.	1.4	1
243	Toward a new taxonomy of obstetrical disease: improved performance of maternal blood biomarkers for the great obstetrical syndromes when classified according to placental pathology. American Journal of Obstetrics and Gynecology, 2022, 227, 615.e1-615.e25.	0.7	24
244	Correlation of sFlt-1/PlGF and Placental CD146 with Preeclampsia. Advances in Clinical Medicine, 2022, 12, 8294-8304.	0.0	0
245	Human Plasma Proteome During Normal Pregnancy. Journal of Proteome Research, 2022, 21, 2687-2702.	1.8	7
246	Preeclampsia at term can be classified into 2 clusters with different clinical characteristics and outcomes based on angiogenic biomarkers in maternal blood. American Journal of Obstetrics and Gynecology, 2023, 228, 569.e1-569.e24.	0.7	12
247	Blood biomarkers to predict the onset of pre-eclampsia: A systematic review and meta-analysis. Heliyon, 2022, 8, e11226.	1.4	8
248	Similar Pro- and Antiangiogenic Profiles Close to Delivery in Different Clinical Presentations of Two Pregnancy Syndromes: Preeclampsia and Fetal Growth Restriction. International Journal of Molecular Sciences, 2023, 24, 972.	1.8	7
249	Proteomic profile of extracellular vesicles in maternal plasma of women with fetal death. Journal of Maternal-Fetal and Neonatal Medicine, 2023, 36, .	0.7	2
250	Preeclampsia pathophysiology and adverse outcomes during pregnancy and postpartum. Frontiers in Medicine, 0, 10, .	1.2	14
251	Accuracy of placental growth factor alone or in combination with soluble fms-like tyrosine kinase-1 or maternal factors in detecting preeclampsia in asymptomatic women in the second and third trimesters: a systematic review and meta-analysis. American Journal of Obstetrics and Gynecology, 2023, 229, 222-247.	0.7	6